News | Cardiovascular Business | November 04, 2015

Bard Agrees to Acquire Full Ownership of its Joint Venture in Japan

Company expects to see future growth opportunities in peripheral vascular and vascular access markets

November 4, 2015 — C.R. Bard Inc. announced in late September that it has entered into a definitive agreement to acquire Kobayashi Pharmaceutical’s 50 percent ownership share in Medicon Inc., the Osaka, Japan-based joint venture of the two companies, through a share redemption. The transaction is expected to close in early November 2015, after which Medicon will be a wholly-owned subsidiary of the company. The transaction has been approved by each company’s board of directors and is subject to customary closing conditions.

Bard and Kobayashi have jointly operated Medicon for over 40 years. In recent years, Medicon has built clinical and regulatory capabilities that have allowed the business to more effectively introduce new products. At the same time, Bard has demonstrated the ability to execute its product leadership strategy with a direct selling model in international markets. Today, the company believes that the future growth opportunities in Japan will come from market segments that are more clinically differentiated, including peripheral vascular and vascular access. Therefore, the company believes that now is the time to take a more direct role with clinicians and patients in Japan.

The company expects the transaction to add approximately $40 million to 2016 net sales. On an operational basis (excluding the impact of foreign exchange), the company expects the transaction to be neutral to adjusted cash earnings per share both in the fourth quarter of 2015 and the full-year 2016, and to be accretive thereafter. Including the impact of foreign exchange, the company expects the transaction to reduce fourth quarter 2015 and full year 2016 adjusted cash earnings per share by approximately 5 cents and 20 cents, respectively.

As consideration for the transaction, Kobayashi will receive 3 billion yen at closing. Kobayashi will also receive the following additional payments annually on the anniversary date of the transaction: 1.9 billion yen in 2016, 1.5 billion yen in 2017, 1.2 billion yen in 2018, 1 billion yen in 2019, 600 million yen in both 2020 and 2021, 400 million yen in both 2022 and 2023, and 300 million yen in both 2024 and 2025; the total consideration being 11.2 billion yen.

For more information: www.crbard.com

Related Content

Researchers raised the question whether an economic benefit should be assessed in FDA reviews. A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters.

A large amount of the bill for atrial fibrillation catheter ablation procedures is the cost of the mapping and ablation catheters. Researchers raised the question whether an economic benefit should be assessed in FDA reviews. 

Feature | Cardiovascular Business | January 14, 2019 | Philip Jacobs, DPhil, Ilke Akpinar, M.D., Thanh Nguyen, M.D., Ph.D., Rupinder Sandhu, M.D., and Lars Thording Ph.D.
In an age when everything in medicine is now looked at though a cost vs. benefit analysis and U.S.
GE Submits Initial Public Offering Paperwork for Healthcare Division
News | Cardiovascular Business | December 19, 2018
As part of its plans to spin off its healthcare division into a separate company, GE reportedly submitted the paperwork...
Affordable Care Act Ruled Unconstitutional in Texas Federal Court
News | Cardiovascular Business | December 17, 2018
A judge of the Federal District Court for the Northern District of Texas ruled the Affordable Care Act (ACA)...
Average Age of U.S. Cardiologists Up While Income is Down
News | Cardiovascular Business | October 25, 2018
Overall cardiology compensation has dropped for the first time since 2014, according to the sixth annual Cardiovascular...
American Heart Association and The Joint Commission Merge Cardiac Certification Programs
News | Cardiovascular Business | October 15, 2018
The nation’s two leading cardiac accreditation and certification organizations are joining forces to offer a single...
ZHealth Launches Etch Cardiovascular Coding Software
Technology | Cardiovascular Business | October 10, 2018
October 10, 2018 — Medical coding software provider ZHealth recently unveiled Etch, the first-ever software platform
A hands-on-training session at TCT 2018 that instructed interventional cardiologists how to use an intra-cardiac echo (ICE) catheter to image the chambers inside the heart with a catheter based ultrasound imaging system.  The training area was sponsored by Siemens Healthineers

A Siemens-sponsored hands-on-training session at TCT 2018 that instructed interventional cardiologists how to use an intra-cardiac echo (ICE) catheter to image the chambers inside the heart with a catheter based ultrasound imaging system.  Regular training is needed to build customer satisfaction, especially in light of regular staff turnover.

Feature | Cardiovascular Business | October 10, 2018 | John Larson
Years ago, I owned a computer that ran a spreadsheet program called Lotus 1-2-3.
GlobalData: Amazon Poised to Make Huge Strides in Healthcare
News | Cardiovascular Business | August 31, 2018
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in...
CMS Proposes Overhaul of Medicare's Accountable Care Organization Program
News | Cardiovascular Business | August 09, 2018
The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule August 9 that would overhaul the Medicare...
ECRI Institute Announces New Clinical Guideline Repository Website
News | Cardiovascular Business | July 27, 2018
July 27, 2018 — Following the deactivation of the National Guideline Clearinghouse (NGC) by the Agency for Healthcare
Overlay Init